Home Newsfeeds ‘McDonald’s ends McPlant test’ -Crain’s Chicago Business

News

‘McDonald’s ends McPlant test’ -Crain’s Chicago Business

https://www.chicagobusiness.com/restaurants/mcdonalds-ends-us-mcplant-test-meatless-burger-beyond-meat

byBill Haddad

July 29, 2022

1 minute read

https://www.chicagobusiness.com/restaurants/mcdonalds-ends-us-mcplant-test-meatless-burger-beyond-meat

Artesian Resources Corporation Announces Pricing Of $34.8M Public Offering Of 695,650 Shares Of Common Stock At A Price Of $50/Share

By Happy Mohamed

May 19, 9:35 AM

Artesian Resources Corporation (NASDAQ:ARTNA) (Artesian or the Company) announced today that it has priced a firm commitment underwritten public offering of 695,650 shares of the Company's Class A

ARTNA

News

Olema Oncology Earlier Announced Phase 2 Monotherapy Clinical Study Results For Palazestrant; Showed Results Support Continued Development Of Palazestrant In The OPERA-01 Monotherapy Phase 3 Pivotal Trial

By Charles Gross

October 22, 11:11 AM

Olema Pharmaceuticals, Inc. ((&ldquo, Olema&rdquo, , &ldquo, Olema Oncology&rdquo, , or the &ldquo, Company&rdquo, , NASDAQ:OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and

OLMA

News

Inotiv Completes Hillcrest, UK Expansion, Secures Long-Term Contracts with New Customers

By Benzinga Newsdesk

June 10, 7:37 AM

Inotiv, Inc. (NASDAQ:NOTV) (the "Company" or "Inotiv"), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research

NOTV

Golden Ticket To California Cannabis Retail? Gold Flora’s Valuation & Potential, Overweight Initiation By Zuanic

By Nicolas Jose Rodriguez

January 11, 10:55 PM

Equity research firm Zuanic & Associates led by senior analyst Pablo Zuanic has initiated coverage of Gold Flora (OTC: GRAM) with an Overweight rating.

GRAM

‘McDonald’s ends McPlant test’ -Crain’s Chicago Business

Related Posts

Artesian Resources Corporation Announces Pricing Of $34.8M Public Offering Of 695,650 Shares Of Common Stock At A Price Of $50/Share

Olema Oncology Earlier Announced Phase 2 Monotherapy Clinical Study Results For Palazestrant; Showed Results Support Continued Development Of Palazestrant In The OPERA-01 Monotherapy Phase 3 Pivotal Trial

Inotiv Completes Hillcrest, UK Expansion, Secures Long-Term Contracts with New Customers

Golden Ticket To California Cannabis Retail? Gold Flora’s Valuation & Potential, Overweight Initiation By Zuanic